Market closed
MacroGenics/$MGNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MacroGenics
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Ticker
$MGNX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
341
ISIN
US5560991094
Website
MacroGenics Metrics
BasicAdvanced
$97M
-
-$1.07
2.11
-
Price and volume
Market cap
$97M
Beta
2.11
52-week high
$14.91
52-week low
$0.99
Average daily volume
862K
Financial strength
Current ratio
3.917
Quick ratio
3.709
Long term debt to equity
28.087
Total debt to equity
32.278
Interest coverage (TTM)
-99.17%
Management effectiveness
Return on assets (TTM)
-24.68%
Return on equity (TTM)
-49.85%
Valuation
Price to revenue (TTM)
0.643
Price to book
0.83
Price to tangible book (TTM)
0.83
Price to free cash flow (TTM)
-1.338
Growth
Revenue change (TTM)
155.26%
Earnings per share change (TTM)
631.14%
3-year revenue growth (CAGR)
24.64%
3-year earnings per share growth (CAGR)
-31.80%
What the Analysts think about MacroGenics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MacroGenics stock.
MacroGenics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MacroGenics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MacroGenics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MacroGenics stock?
MacroGenics (MGNX) has a market cap of $97M as of May 10, 2025.
What is the P/E ratio for MacroGenics stock?
The price to earnings (P/E) ratio for MacroGenics (MGNX) stock is 0 as of May 10, 2025.
Does MacroGenics stock pay dividends?
No, MacroGenics (MGNX) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next MacroGenics dividend payment date?
MacroGenics (MGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for MacroGenics?
MacroGenics (MGNX) has a beta rating of 2.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.